Genome-wide association study on overall survival of advanced non-small cell lung cancer patients treated with carboplatin and paclitaxel

Journal of Thoracic Oncology

Volumn 6, Issue 1, 2011, Pages 132-138

  Sato, Yasunori ^a,b   Yamamoto, Noboru ^c   Kunitoh, Hideo ^c,d   Ohe, Yuichiro ^c   Minami, Hironobu ^e,f   Laird, Nan M ^b   Katori, Noriko ^g   Saito, Yoshiro ^h   Ohnami, Sumiko ^a   Sakamoto, Hiromi ^a   Sawada, Jun Ichi ⁱ   Saijo, Nagahiro ^e   Yoshida, Teruhiko ^a   Tamura, Tomohide ^c  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c National Cancer Center Hospital   (United States)

^d MITSUI MEMORIAL HOSPITAL   (Japan)

^e NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^f KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g Divisions of Drugs   (Japan)

^h Medicinal Safety Science   (Japan)

ⁱ NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

Author keywords

Advanced non small lung cancer; Carboplatin; Genome wide association study; Paclitaxel; Single nucleotide polymorphisms

Indexed keywords

CARBOPLATIN; PACLITAXEL; SOMATOMEDIN B RECEPTOR;

ADULT; ADVANCED CANCER; AGED; ANEMIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CNTNAP4 GENE; DIARRHEA; DRUG CLEARANCE; DSCAM GENE; EIF3E2 GENE; ETS2 GENE; FEBRILE NEUTROPENIA; FEMALE; GENE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HYPERBILIRUBINEMIA; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHARMACOGENOMICS; PRIORITY JOURNAL; SCIN GENE; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

EID: 78651096047     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318200f415     Document Type: Article

References (41)

1. Cancer Statistics in Japan 2008: The Editorial Board of the Cancer Statistics in Japan. Tokyo, Japan: Foundation for Promotion of Cancer Research 2008. Available at: http://www.fpcr.or.jp/publication/statistics.html. Accessed March 3, 2010.
2. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 1995;311: 899-909.
3. Fukuoka M, Niitani H, Suzuki A, et al. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol 1992;10:16-20.
4. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med 1995; 332:1004-1014.
5. Gelmon K. The taxoids: paclitaxel and docetaxel. Lancet 1994;344: 1267-1272.
6. Hertel LW, Border GB, Kroin JS, et al. Evaluation of the antitumor activity of gemcitabine. Cancer Res 1990;50:4417-4422.
7. Binet S, Fellous A, Lataste H, et al. Biochemical effects of navelbine on tubulin and associated proteins. Semin Oncol 1989;16:9-14.
8. Petris L, Crino L, Scagliotti GV, et al. Treatment of advanced non-small cell lung cancer. Ann Oncol 2006;17(Suppl 2):ii36 -ii41.
9. Kubota K, Kawahara M, Ogawara M, et al. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study. Lancet Oncol 2008;9:1135-1142.
10. Bepler G. Using translational research to tailor the use of chemotherapy in the treatment of NSCLC. Lung Cancer 2005;50(Suppl 1):S13-S14.
11. Rosell R, Cobo M, Isla D, et al. Applications of genomics in NSCLC. Lung Cancer 2005;50:S33-S40.
12. Nakajima Y, Yoshitani T, Fukushima-Uesaka H, et al. Impact of the haplotype CYP3A4*16B harboring the Thr185Ser substitution on paclitaxel metabolism in Japanese patients with cancer. Clin Pharmacol Ther 2006;80:179-191.
13. Saito Y, Katori N, Soyama A, et al. CYP2C8 haplotype structures and their influence on pharmacokinetics of paclitaxel in a Japanese population. Pharmacogenet Genomics 2007;17:461-471.
14. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
15. Cox, DR. Regression models and life tables. J R Stat Soc 1972;34:187-220.
16. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York, NY: John Wiley and Sons, 1980.
17. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat 1979;6:65-70.
18. Gurubhagavatula S, Liu G, Park S, et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 2004;22:2594-2601.
19. Isla D, Sarries C, Rosell R, et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol 2004;15:1194-1203.
20. Ryu JS, Hong YC, Han HS, et al. Association between polymorphisms of ERCC1 and XPD and survival in non-small cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 2004; 44:311-316.
21. de las Penas R, Sanchez-Ronco M, Alberola V, et al. Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. Ann Oncol 2006;17:668-675.
22. Booton R, Ward T, Heighway J, et al. Xeroderma pigmentosum group D haplotype predicts for response, survival, and toxicity after platinumbased chemotherapy in advanced nonsmall cell lung cancer. Cancer 2006;106:2421-2427.
23. Spitz MR, Wu X, Wang Y, et al. Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res 2001;61:1354-1357.
24. Duell EJ, Wiencke JK, Cheng TJ, et al. Polymorphisms in the DNA repair genes XRCC1 and ERCC2 and biomarkers of DNA damage in human blood mononuclear cells. Carcinogenesis 2000;21:965-971.
25. Matullo G, Palli D, Peluso M, et al. XRCC1, XRCC3, XPD gene polymorphisms, smoking and (32)P-DNA adducts in a sample of healthy subjects. Carcinogenesis 2001;22:1437-1445.
26. Bosken CH, Wei Q, Amos CI, et al. An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer. J Natl Cancer Inst 2002;94:1091-1099.
27. Wei Q, Wang X, Shen H. DNA repair gene XPD polymorphism and lung cancer risk: a meta-analysis. Lung Cancer 2004;46:1-10.
28. Chen J, Larochelle S, Li X, et al. Xpd/Ercc2 regulates CAK activity and mitotic progression. Nature 2003;424:228-232.
29. Hirschhorn JN, Daly MJ. Genome-wide association studies for common diseases and complex traits. Nat Rev Genet 2005;6:95-108.
30. Nordborg M, Tavaré B. Linkage disequilibrium: what history has to tell us. Trends Genet 2002;18:83-90.
31. Gingras AC, Raught B, Sonenberg N. eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. Annu Rev Biochem 1999;68:913-963.
32. Gross JD, Moerke NJ, von der Haar T, et al. Ribosome loading onto the mRNA cap is driven by conformational coupling between eIF4G and eIF4E. Cell 2003;115:739-750.
33. Joshi B, Cameron A, Jagus R. Characterization of mammalian eIF4Efamily members. Eur J Biochem 2004;271:2189-2203.
34. Okumura F, Zou W, Zhang DE. ISG15 modification of the eIF4E cognate 4EHP enhances cap structure-binding activity of 4EHP. Genes Dev 2007;21:255-260.
35. Rom E, Kim HC, Gingras AC, et al. Cloning and characterization of 4EHP, a novel mammalian eIF4E-related cap-binding protein. J Biol Chem 1998;273:13104-13109.
36. Ramaswamy S, Ross KN, Lander ES, et al. A molecular signature of metastasis in primary solid tumors. Nat Genet 2003;33:49-54.
37. Foos G, Hauser CA. Altered Ets transcription factor activity in prostate tumor cells inhibits anchorage-independent growth, survival, and invasiveness. Oncogene 2000;19:5507-5516.
38. Yamakawa K, Huo Y-K, Haendel MA, et al. DSCAM: a novel member of the immunoglobulin superfamily maps in a Down syndrome region and is involved in the development of the nervous system. Hum Mol Genet 1998;7:227-237.
39. Wojtowicz WM, Flanagan JJ, Millard S, et al. Alternative splicing of Drosophila Dscam generates axon guidance receptors that exhibit isoform- specific homophilic binding. Cell 2004;118:619-633.
40. Fuerst PG, Koizumi A, Masland RH, et al. Neurite arborization and mosaic spacing in the mouse retina require DSCAM. Nature 2008;451: 470-474.
41. Coe BP, Lockwood WW, Girard L, et al. Differential disruption of cell cycle pathways in small cell and non-small cell lung cancer. Br J Cancer 2006;94:1927-1935.